Please login to the form below

Not currently logged in
Email:
Password:

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

New data keeps AbbVie’s star pipeline therapies on track

follow-up to its marketed JAK inhibitor Xeljanz (tofacitinib). ... And for good measure Pfizer is developing a topical formulation of Xeljanz for atopic dermatitis, an approach also taken by Torii Pharma with its phase II candidate JTE-052.

Latest news

More from news
Approximately 17 fully matching, plus 44 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

  • Brand leaders in RA will lose market share, predict rheumatologists

    JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics